» Articles » PMID: 17192641

Effect of Acetylcholinesterase Inhibitors on AChE-induced PrP106-126 Aggregation

Overview
Journal J Mol Neurosci
Date 2006 Dec 29
PMID 17192641
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Transmissible spongiform encephalopaties are caused by an extracellular surface protein, the scrapie prion protein (PrPsc), which is an aberrant form of normal and functional cellular PrP (PrPc). The pathological hallmarks of these diseases are the accumulation and deposition of PrPsc in the form of amyloid fibrils in the central nervous system (Tateishi et al., 1988), similar to amyloid-beta (Abeta) protein in Alzheimer's disease (AD). In some patients, Abeta and prion pathology can coexist (Hainfellner et al., 1998), and a common spatial pattern of protein deposition has been described (Armstrong et al., 2001). In addition, it is well-known that acetylcholinesterase (AChE) colocalizes with Abeta deposits of brains in AD patients and accelerates assembly of Abeta peptides through the peripheral site of the enzyme (Inestrosa et al., 1996). The aim of the present study was to analyze time course and concentration dependence of the AChE proaggregating effect on synthetic peptide-spanning residues 106-126 of human PrP (PrP106-126) and the reversion of this effect by different AChE inhibitors (AChEIs).

Citing Articles

Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3.

Gimenez-Llort L, Santana-Santana M, Ratia M, Perez B, Camps P, Munoz-Torrero D Brain Sci. 2021; 11(4).

PMID: 33810622 PMC: 8065516. DOI: 10.3390/brainsci11040426.


Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706.

Carvajal F, Inestrosa N Front Mol Neurosci. 2011; 4:19.

PMID: 21949501 PMC: 3172730. DOI: 10.3389/fnmol.2011.00019.


Multiple approaches to analyse the data for rat brain acetylcholinesterase inhibition by cyclophosphamide.

Kamal M, Reale M, Al-Jafari A Neurochem Res. 2010; 35(10):1501-9.

PMID: 20652634 DOI: 10.1007/s11064-010-0199-y.

References
1.
Hainfellner J, Wanschitz J, Jellinger K, Liberski P, Gullotta F, Budka H . Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998; 96(2):116-22. DOI: 10.1007/s004010050870. View

2.
Inestrosa N, Alvarez A, Perez C, Moreno R, Vicente M, Linker C . Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996; 16(4):881-91. DOI: 10.1016/s0896-6273(00)80108-7. View

3.
Tateishi J, Kitamoto T, Hashiguchi H, Shii H . Gerstmann-Sträussler-Scheinker disease: immunohistological and experimental studies. Ann Neurol. 1988; 24(1):35-40. DOI: 10.1002/ana.410240108. View

4.
Camps P, El Achab R, Gorbig D, Morral J, Munoz-Torrero D, Badia A . Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J Med Chem. 1999; 42(17):3227-42. DOI: 10.1021/jm980620z. View

5.
Bartolini M, Bertucci C, Cavrini V, Andrisano V . beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol. 2003; 65(3):407-16. DOI: 10.1016/s0006-2952(02)01514-9. View